Global BioLife, Chemia to Develop Functional Fragrances for Medical Applications

Singapore eDevelopment Limited (SeD) said that its indirect subsidiary, Global BioLife Inc (Global BioLife) will collaborate with US-based Chemia Corporation (Chemia) to develop specialised fragrances to counter mosquito-borne diseases and stress and anxiety, and for anti-viral medical applications.

3F (functional fragrance formulation) is a suite of functional fragrances developed for industrial and medical applications. The first product in 3F’s suite of functional fragrances is 3F Mosquito which is made up of specialised oils sourced from botanicals that mosquitoes avoid.

The objective in the design of 3F Mosquito was to identify and create a suitable formula that is both pleasant and excels in providing layers of protection against mosquitoes. Global BioLife has formed a working collaboration with Chemia to develop the 3F suite of functional fragrances for addition into laundry detergents, shampoos and lotions to provide additional layers of protection against mosquitoes, as well as developing new advanced coatings for industrial and medical applications.

Daryl Thompson, Global BioLife’s director of scientific initiatives, leads the 3F research.

In addition to 3F Mosquito, Global BioLife is working with Chemia on the development of additional 3F functional fragrances to fight stress and anxiety, and for anti-viral medical applications, as well as developing new advanced coatings for industrial and medical applications.

Global BioLife is an 80 percent-held subsidiary of SeD’s wholly-owned Global BioMedical Inc. The remaining shareholding in Global BioLife is held by Thompson’s GRDG Sciences LLC and Australia Securities Exchange-listed Holista CollTech Limited in equal proportions of 10 percent each.

“The specialised oils in 3F Mosquito are scientifically proven to affect mosquito’s receptors, essentially making the mosquito blind to your presence,” said Thompson.

“Biomedical science has become increasingly vital. Global BioLife is proud to be taking steps to provide solutions to issues that have been plaguing the biomedical field for decades. This working collaboration marks one of the first steps in actively changing the game of healthcare,” said Chan Heng Fai, SeD’s executive chairman and CEO and also Global BioLife’s director.